Trial Profile
A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection and Human Immunodeficiency Virus-1 (HIV-1) Co-Infection (EXPEDITION-2)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Sep 2022
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms EXPEDITION-2
- Sponsors AbbVie; AbbVie Germany
- 04 Aug 2022 Results assessing the performance of these alternative models relative to MMRM using both simulated data and the real trial data from the EXPEDITION 1 and EXPEDITION-2 placebo arms, presented at the Alzheimer's Association International Conference 2022.
- 05 Jun 2018 Results of pooled data from 10 studies (SURVEYOR-I, -II, MAGELLAN-I, ENDURANCE-1, -2, -3, -4, EXPEDITION-1, -2 and -4; n=2522 ),were presented at the Digestive Disease Week 2018.
- 14 Apr 2018 Results of an integrated analysis of 10 studies (SURVEYOR-I, -II, MAGELLAN-I, ENDURANCE-1, -2, -3, -4, EXPEDITION-1, -2 and -4; n=789) assessing efficacy and safety in patients with psychiatric disorders, presented at The International Liver Congress 2018